For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, 2seventy bio Inc’s stock clocked out at $4.59, up 7.87% from its previous closing price of $4.26. In other words, the price has increased by $7.87 from its previous closing price. On the day, 0.67 million shares were traded. TSVT stock price reached its highest trading level at $4.66 during the session, while it also had its lowest trading level at $4.19.
Ratios:
To gain a deeper understanding of TSVT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.98 and its Current Ratio is at 3.98. In the meantime, Its Debt-to-Equity ratio is 1.01 whereas as Long-Term Debt/Eq ratio is at 0.96.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on January 31, 2024, Upgraded its rating to Outperform and sets its target price to $18 from $5 previously.
Leerink Partners Downgraded its Outperform to Market Perform on October 30, 2023, while the target price for the stock was maintained at $6.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 26 ’24 when Casdin Capital, LLC bought 40,000 shares for $5.10 per share. The transaction valued at 203,992 led to the insider holds 2,000,000 shares of the business.
Casdin Capital, LLC bought 330,000 shares of TSVT for $1,673,991 on Mar 25 ’24. The Director now owns 1,960,000 shares after completing the transaction at $5.07 per share. On Mar 22 ’24, another insider, Casdin Capital, LLC, who serves as the Director of the company, bought 147,377 shares for $5.12 each. As a result, the insider paid 754,069 and bolstered with 1,630,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TSVT now has a Market Capitalization of 235517952 and an Enterprise Value of 275202080. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.35 while its Price-to-Book (P/B) ratio in mrq is 0.91. Its current Enterprise Value per Revenue stands at 2.741 whereas that against EBITDA is -1.333.
Stock Price History:
The Beta on a monthly basis for TSVT is 1.90, which has changed by -0.5491159 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, TSVT has reached a high of $12.69, while it has fallen to a 52-week low of $1.53. The 50-Day Moving Average of the stock is -9.11%, while the 200-Day Moving Average is calculated to be -0.00%.
Shares Statistics:
It appears that TSVT traded 1.46M shares on average per day over the past three months and 902470 shares per day over the past ten days. A total of 50.63M shares are outstanding, with a floating share count of 47.64M. Insiders hold about 7.16% of the company’s shares, while institutions hold 93.32% stake in the company. Shares short for TSVT as of 1713139200 were 6480171 with a Short Ratio of 4.43, compared to 1710460800 on 5251132. Therefore, it implies a Short% of Shares Outstanding of 6480171 and a Short% of Float of 12.78.
Earnings Estimates
The firm’s stock currently is rated by 6.0 analysts. On average, analysts expect EPS of -$0.81 for the current quarter, with a high estimate of -$0.49 and a low estimate of -$0.96, while EPS last year was -$1.08. The consensus estimate for the next quarter is -$0.63, with high estimates of -$0.21 and low estimates of -$0.95.
Analysts are recommending an EPS of between -$0.09 and -$3.28 for the fiscal current year, implying an average EPS of -$1.94. EPS for the following year is -$0.68, with 7.0 analysts recommending between $1.39 and -$1.79.
Revenue Estimates
In the current quarter, 6 analysts expect revenue to total $14.08M. It ranges from a high estimate of $16.7M to a low estimate of $10.47M. As of the current estimate, 2seventy bio Inc’s year-ago sales were $22.3MFor the next quarter, 6 analysts are estimating revenue of $17.2M. There is a high estimate of $26.66M for the next quarter, whereas the lowest estimate is $11.17M.
A total of 7 analysts have provided revenue estimates for TSVT’s current fiscal year. The highest revenue estimate was $125.2M, while the lowest revenue estimate was $54.5M, resulting in an average revenue estimate of $79.19M. In the same quarter a year ago, actual revenue was $100.39MBased on 7 analysts’ estimates, the company’s revenue will be $101.02M in the next fiscal year. The high estimate is $153.15M and the low estimate is $59.25M.
